Financial Contrast: Seres Therapeutics (NASDAQ:MCRB) and OS Therapies (NYSE:OSTX)

Seres Therapeutics (NASDAQ:MCRB) and OS Therapies (NYSE:OSTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Profitability

This table compares Seres Therapeutics and OS Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	N/A	-46.67%
OS Therapies	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Seres Therapeutics and OS Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	0	1	2	0	2.67
OS Therapies	0	0	0	2	4.00

Seres Therapeutics presently has a consensus target price of $5.08, indicating a potential upside of 514.30%. Given Seres Therapeutics’ higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than OS Therapies.

Earnings & Valuation

This table compares Seres Therapeutics and OS Therapies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$374,000.00	333.10	-$113.72 million	($0.60)	-1.37
OS Therapies	N/A	N/A	-$7.79 million	N/A	N/A

OS Therapies has lower revenue, but higher earnings than Seres Therapeutics.

Insider and Institutional Ownership

59.3% of Seres Therapeutics shares are held by institutional investors. 5.1% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Seres Therapeutics beats OS Therapies on 5 of the 9 factors compared between the two stocks.

About Seres Therapeutics

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.